Enliven Therapeutics' ELVN-001 Shows Promising Trial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 21 2026
0mins
Source: Fool
Enliven Therapeutics Inc's stock surged by 54.69% as it crossed above the 20-day SMA, reflecting strong investor interest amid mixed market conditions.
This significant price movement is attributed to the announcement that ELVN-001 achieved a 69% major molecular response rate at 24 weeks in its Phase 1b trial for chronic myeloid leukemia, indicating its potential as a leading treatment option. Additionally, the appointment of Scott Garland to the Board, aimed at advancing the commercialization of ELVN-001, further bolstered investor confidence in the company's strategic direction.
The positive trial results and leadership changes position Enliven Therapeutics favorably in the competitive biopharma landscape, suggesting a strong outlook for the future development and market introduction of ELVN-001.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ELVN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ELVN
Wall Street analysts forecast ELVN stock price to fall
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 50.010
Low
35.00
Averages
40.67
High
48.00
Current: 50.010
Low
35.00
Averages
40.67
High
48.00
About ELVN
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). ELVN-001 is an adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor (TKI). The Company's second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Enliven Therapeutics Director Sells Shares Amid Rising Investor Sentiment
- Share Reduction Details: On June 5, 2026, Enliven Therapeutics Director Lori Anne Kunkel sold 10,000 shares at an average price of $34.54, totaling approximately $345,000, reducing her holdings from 61,884 to 51,884 shares, indicating her confidence in the company's future.
- Positive Market Reaction: At the time of the sale, Enliven's stock had risen 62% over the past year and achieved a staggering 130% gain over 12 months, reflecting growing investor optimism regarding the company's pipeline, particularly the ELVN-001 candidate for chronic myeloid leukemia.
- Strong Financial Position: As of the first quarter, Enliven held $452.4 million in cash and cash equivalents, expected to fund operations into the first half of 2029, and further strengthened its balance sheet by closing an upsized public offering that raised approximately $460 million.
- Clinical Trial Outlook: The company is preparing to launch its Phase 3 ENABLE-2 trial for chronic myeloid leukemia, with CEO Rick Fair stating that ELVN-001 has the potential to become a best-in-class therapy, making upcoming clinical milestones crucial for meeting market expectations.
See More
Enliven Therapeutics Director Sells Shares
- Transaction Overview: Enliven Therapeutics Director Lori Anne Kunkel sold 10,000 shares of common stock for approximately $345,000 on June 5, 2026, marking her first open-market sale and reducing her direct holdings by 16% to 51,884 shares, indicating confidence in the company's future.
- Transaction Context: This sale was executed under a Rule 10b5-1 trading plan adopted on March 6, 2026, reflecting Kunkel's stock management strategy rather than a negative signal about the company's outlook, especially as the stock had appreciated 62.4% over the past year at the time of sale.
- Market Performance and Outlook: As of June 5, 2026, Enliven Therapeutics' stock price was $34.54, with a market capitalization of $2.81 billion, and future revenue is expected from product commercialization or strategic partnerships, particularly with the ELVN-001 candidate for chronic myeloid leukemia entering Phase 3 trials soon.
- Investor Sentiment and Company Strategy: Despite Kunkel's share reduction, the company's stock has surged 130% over the past 12 months, reflecting optimistic investor sentiment towards Enliven's pipeline, with management stating they have $452.4 million in cash reserves to fund operations into the first half of 2029, making upcoming clinical milestones crucial.
See More
Enliven Therapeutics Director Sells 10,000 Shares Amid 130% Stock Surge
- Transaction Overview: On June 5, 2026, Enliven Therapeutics Director Lori Anne Kunkel sold 10,000 shares of common stock for approximately $345,000, marking her first open-market sale and reflecting confidence in the company's future prospects.
- Change in Holdings: This transaction reduced Kunkel's direct holdings from 61,884 shares to 51,884 shares, representing 16% of her total direct stock ownership, while her indirect or derivative positions remained unaffected, indicating sustained confidence in the company.
- Market Performance Context: At the time of the sale, Enliven Therapeutics shares had appreciated by 62.4% over the past year, closing at $34.71 on the transaction date, which underscores the market's optimism regarding its pipeline, particularly the ELVN-001 candidate for chronic myeloid leukemia.
- Future Development Potential: The company is set to launch the Phase 3 ENABLE-2 trial for ELVN-001 later in 2026, with the CEO stating that the drug has the potential to become a best-in-class therapy, supported by a robust cash reserve of $452.4 million, indicating a positive outlook for future growth.
See More
Orbimed Advisors Sells 860,123 Shares of Enliven Therapeutics
- Transaction Overview: On June 22, 2026, Orbimed Advisors indirectly sold 860,123 shares of Enliven Therapeutics for approximately $39 million, indicating a significant yet retained ownership stake in the company.
- Ownership Proportion Change: This sale represented an 11.60% reduction in Orbimed's indirect holdings, yet they still hold over 6.5 million shares, reflecting ongoing confidence in Enliven despite profit-taking.
- Market Reaction Analysis: The shares were sold at around $45.36 each, slightly below the closing price of $45.96 on the transaction date, with a subsequent rise to $50 by June 26, indicating positive market sentiment.
- Financial Status and Outlook: Enliven's market capitalization stands at $3.6 billion, with a net loss of $98.78 million over the past year; however, a 130% stock price increase and a robust cash position of $452.4 million support future clinical trials and product development efforts.
See More
Orbimed Advisors Sells ELVN Shares Worth $39 Million
- Sale Overview: On June 22, 2026, Orbimed Advisors sold 860,123 shares of ELVN for approximately $39 million at an average price of $45.36 per share, representing 11.60% of their total indirect holdings, indicating a strategic profit-taking approach while maintaining market confidence.
- Ownership Change: Following the sale, Orbimed's indirect ownership decreased from 7,415,225 shares to 6,555,102 shares, yet they remain a major shareholder, reflecting continued conviction in Enliven Therapeutics despite the reduction in holdings.
- Financial Position: Enliven Therapeutics ended Q1 2026 with $452.4 million in cash and cash equivalents, which is expected to fund operations into the first half of 2029, showcasing the company's financial stability and growth potential.
- Clinical Progress: Enliven recently announced positive data from the ELVN-001 clinical trial and plans to launch the pivotal Phase 3 ENABLE-2 trial in the second half of the year, with the CEO highlighting the unmet need in the CML market as a compelling long-term opportunity for the therapy.
See More
Orbimed Advisors Reduces Stake in Enliven Therapeutics
- Sale Overview: Orbimed Advisors recently sold 281,408 shares of Enliven Therapeutics for approximately $12.67 million, representing 3.67% of its indirect holdings, indicating a strategic decision while maintaining a significant investment in the company.
- Holding Analysis: Post-transaction, Orbimed continues to hold 7,388,902 shares indirectly, suggesting a sustained commitment to Enliven despite the recent sale, which reflects confidence in the company's future prospects.
- Market Reaction and Impact: This sale occurred shortly after Enliven announced promising clinical trial data for a leukemia drug, potentially indicating Orbimed's assessment of a market peak, although it does not necessarily imply a negative outlook on the company's future.
- Investor Considerations: As a long-term investor holding over 10% of the company, Orbimed's sale raises market awareness, prompting investors to interpret this move cautiously, as it may be driven by liquidity needs or portfolio rebalancing rather than a negative view on Enliven's fundamentals.
See More
Enliven Therapeutics Director Sells Shares Amid Rising Investor Sentiment
- Share Reduction Details: On June 5, 2026, Enliven Therapeutics Director Lori Anne Kunkel sold 10,000 shares at an average price of $34.54, totaling approximately $345,000, reducing her holdings from 61,884 to 51,884 shares, indicating her confidence in the company's future.
- Positive Market Reaction: At the time of the sale, Enliven's stock had risen 62% over the past year and achieved a staggering 130% gain over 12 months, reflecting growing investor optimism regarding the company's pipeline, particularly the ELVN-001 candidate for chronic myeloid leukemia.
- Strong Financial Position: As of the first quarter, Enliven held $452.4 million in cash and cash equivalents, expected to fund operations into the first half of 2029, and further strengthened its balance sheet by closing an upsized public offering that raised approximately $460 million.
- Clinical Trial Outlook: The company is preparing to launch its Phase 3 ENABLE-2 trial for chronic myeloid leukemia, with CEO Rick Fair stating that ELVN-001 has the potential to become a best-in-class therapy, making upcoming clinical milestones crucial for meeting market expectations.
See More
Enliven Therapeutics Director Sells Shares
- Transaction Overview: Enliven Therapeutics Director Lori Anne Kunkel sold 10,000 shares of common stock for approximately $345,000 on June 5, 2026, marking her first open-market sale and reducing her direct holdings by 16% to 51,884 shares, indicating confidence in the company's future.
- Transaction Context: This sale was executed under a Rule 10b5-1 trading plan adopted on March 6, 2026, reflecting Kunkel's stock management strategy rather than a negative signal about the company's outlook, especially as the stock had appreciated 62.4% over the past year at the time of sale.
- Market Performance and Outlook: As of June 5, 2026, Enliven Therapeutics' stock price was $34.54, with a market capitalization of $2.81 billion, and future revenue is expected from product commercialization or strategic partnerships, particularly with the ELVN-001 candidate for chronic myeloid leukemia entering Phase 3 trials soon.
- Investor Sentiment and Company Strategy: Despite Kunkel's share reduction, the company's stock has surged 130% over the past 12 months, reflecting optimistic investor sentiment towards Enliven's pipeline, with management stating they have $452.4 million in cash reserves to fund operations into the first half of 2029, making upcoming clinical milestones crucial.
See More
Enliven Therapeutics Director Sells 10,000 Shares Amid 130% Stock Surge
- Transaction Overview: On June 5, 2026, Enliven Therapeutics Director Lori Anne Kunkel sold 10,000 shares of common stock for approximately $345,000, marking her first open-market sale and reflecting confidence in the company's future prospects.
- Change in Holdings: This transaction reduced Kunkel's direct holdings from 61,884 shares to 51,884 shares, representing 16% of her total direct stock ownership, while her indirect or derivative positions remained unaffected, indicating sustained confidence in the company.
- Market Performance Context: At the time of the sale, Enliven Therapeutics shares had appreciated by 62.4% over the past year, closing at $34.71 on the transaction date, which underscores the market's optimism regarding its pipeline, particularly the ELVN-001 candidate for chronic myeloid leukemia.
- Future Development Potential: The company is set to launch the Phase 3 ENABLE-2 trial for ELVN-001 later in 2026, with the CEO stating that the drug has the potential to become a best-in-class therapy, supported by a robust cash reserve of $452.4 million, indicating a positive outlook for future growth.
See More
Orbimed Advisors Sells 860,123 Shares of Enliven Therapeutics
- Transaction Overview: On June 22, 2026, Orbimed Advisors indirectly sold 860,123 shares of Enliven Therapeutics for approximately $39 million, indicating a significant yet retained ownership stake in the company.
- Ownership Proportion Change: This sale represented an 11.60% reduction in Orbimed's indirect holdings, yet they still hold over 6.5 million shares, reflecting ongoing confidence in Enliven despite profit-taking.
- Market Reaction Analysis: The shares were sold at around $45.36 each, slightly below the closing price of $45.96 on the transaction date, with a subsequent rise to $50 by June 26, indicating positive market sentiment.
- Financial Status and Outlook: Enliven's market capitalization stands at $3.6 billion, with a net loss of $98.78 million over the past year; however, a 130% stock price increase and a robust cash position of $452.4 million support future clinical trials and product development efforts.
See More
Orbimed Advisors Sells ELVN Shares Worth $39 Million
- Sale Overview: On June 22, 2026, Orbimed Advisors sold 860,123 shares of ELVN for approximately $39 million at an average price of $45.36 per share, representing 11.60% of their total indirect holdings, indicating a strategic profit-taking approach while maintaining market confidence.
- Ownership Change: Following the sale, Orbimed's indirect ownership decreased from 7,415,225 shares to 6,555,102 shares, yet they remain a major shareholder, reflecting continued conviction in Enliven Therapeutics despite the reduction in holdings.
- Financial Position: Enliven Therapeutics ended Q1 2026 with $452.4 million in cash and cash equivalents, which is expected to fund operations into the first half of 2029, showcasing the company's financial stability and growth potential.
- Clinical Progress: Enliven recently announced positive data from the ELVN-001 clinical trial and plans to launch the pivotal Phase 3 ENABLE-2 trial in the second half of the year, with the CEO highlighting the unmet need in the CML market as a compelling long-term opportunity for the therapy.
See More
Orbimed Advisors Reduces Stake in Enliven Therapeutics
- Sale Overview: Orbimed Advisors recently sold 281,408 shares of Enliven Therapeutics for approximately $12.67 million, representing 3.67% of its indirect holdings, indicating a strategic decision while maintaining a significant investment in the company.
- Holding Analysis: Post-transaction, Orbimed continues to hold 7,388,902 shares indirectly, suggesting a sustained commitment to Enliven despite the recent sale, which reflects confidence in the company's future prospects.
- Market Reaction and Impact: This sale occurred shortly after Enliven announced promising clinical trial data for a leukemia drug, potentially indicating Orbimed's assessment of a market peak, although it does not necessarily imply a negative outlook on the company's future.
- Investor Considerations: As a long-term investor holding over 10% of the company, Orbimed's sale raises market awareness, prompting investors to interpret this move cautiously, as it may be driven by liquidity needs or portfolio rebalancing rather than a negative view on Enliven's fundamentals.
See More
